The Filing Desk

Artiva Biotherapeutics

ARTV · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

ARTV · Last close · November 19, 2026
$3.83
Value Artiva Biotherapeutics yourself

Artiva Biotherapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$79 million. The diluted share count rose 117.1%.

Artiva Biotherapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 10, 2026 · 0001193125-26-100135 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$84M
 
Free cash flow
−$79M
 
Return on equity
−56.5%
474.4 pts
Market cap
$196M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Artiva Biotherapeutics does

Artiva Biotherapeutics is a clinical-stage biotech company with no approved products. It is developing natural killer (NK) cell therapies for autoimmune diseases and cancers. NK cells are immune cells; Artiva's come from donors rather than from each patient, and are made ahead of time, frozen and shipped to the treatment site.

Its lead candidate, AlloNK, is a cell therapy meant to work with antibody drugs to clear B cells, the immune cells that drive many autoimmune diseases. It is being tested in patients with rheumatoid arthritis and other autoimmune diseases, and it has received FDA Fast Track designation in refractory rheumatoid arthritis. Artiva is prioritizing refractory rheumatoid arthritis as its lead use.

Artiva also has CAR-NK candidates tested in trials that partners fund, and it holds rights to its programs outside the Asia-Pacific region. Its Affimed collaboration ended in July 2025 after Affimed filed for insolvency. The company has not yet sold a product.

Its biggest risks, as it describes them

  • Having no products approved for sale and a limited operating history.
  • Needing substantial additional funding, which may dilute shareholders.
  • Dependence on AlloNK, whose approach to treating autoimmune disease with NK cells is unproven.
  • Clinical trials that are costly, may be delayed and may show serious side effects.
  • Trade policies, tariffs and trade barriers.
From Artiva Biotherapeutics's annual report on Form 10-K, filed March 10, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Artiva Biotherapeutics lost money in fiscal 2025: a net loss of $84 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments77185108
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage———
Current ratio6.5x15.4x8.6x
Quick ratio6.5x15.4x8.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Artiva Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 7 insiders bought $109.1 million of Artiva Biotherapeutics shares on the open market, and 6 insiders sold $2.4 million, $378,861 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 17, 2026Fred AslanChief Executive Officer, DirectorSold119,771$3.91$468,532Form 4
Nov 17, 2026Christopher HoranChief Tech Operations OfficerSold20,546$3.91$80,374Form 4
Nov 17, 2026Jennifer BushCOO, CLO, Compliance OfficerSold19,217$3.91$75,175Form 4
Nov 17, 2026Subhashis BanerjeeChief Medical OfficerSold4,037$3.91$15,792Form 4
Nov 17, 2026Gines Diego MirallesPresident & Head of R&DSold1,043$3.91$4,080Form 4
Sep 8, 2026Fred AslanChief Executive Officer, DirectorSold plan23,429$10.92$255,845Form 4
Sep 3, 2026Fred AslanChief Executive Officer, DirectorSold61,888$11.16$690,670Form 4
Sep 3, 2026Christopher HoranChief Tech Operations OfficerSold10,366$11.16$115,685Form 4
Sep 3, 2026Jennifer BushCOO, CLO, Compliance OfficerSold8,391$11.16$93,644Form 4
Sep 3, 2026Subhashis BanerjeeChief Medical OfficerSold1,100$11.16$12,276Form 4
Aug 27, 2026Subhashis BanerjeeChief Medical OfficerSold plan8,222$12.01$98,746Form 4
Aug 18, 2026Subhashis BanerjeeChief Medical OfficerSold plan429$12.00$5,148Form 4
The latest 12 of 38 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40−22,280.1%—
Altman Z''8.07−2.34
Accruals ratio−6.6%−4.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positiveFailFail
Cash from operations is positiveFailFail
Return on assets rose—Pass
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rosePassFail
Share count didn't riseFailFail
Gross margin rose——
Revenue rose relative to assets—Fail
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Artiva Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Artiva BiotherapeuticsFY25−100.0%—————
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue3400
Revenue growth—−99.2%−100.0%
Gross profit———
Research and development505070
Operating income−31−67−90
Net income−29−65−84
Diluted EPS (US$)−35.78−5.81−3.43
Diluted shares (millions)11124
Cash flow
Cash from operations−47−55−77
Capital expenditure313
Free cash flow−51−56−79
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation777
Balance sheet at fiscal year end
Cash and short-term investments77185108
Debt incl. finance leases———
Total assets105210131
Total liabilities512321
Shareholders' equity−162187110
Margins and ratios
Gross margin———
Operating margin−91.6%−26,805.6%—
Net margin−85.8%−26,045.0%—
Free cash flow margin−151.3%−22,180.9%—
Rule of 40 (growth + FCF margin)—−22,280.1%—
Return on capital———
Return on equity—−530.9%−56.5%
Return on assets—−41.5%−49.3%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Artiva Biotherapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Artiva Biotherapeutics.